TickerFacts.

Compare

Akebia Therapeutics, Inc. vs Puma Biotechnology, Inc. vs Arcus Biosciences, Inc. vs Arvinas, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAkebia Therapeutics, Inc.
AKBA		Puma Biotechnology, Inc.
PBYI		Arcus Biosciences, Inc.
RCUS		Arvinas, Inc.
ARVN
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$236.20M$228.37M$247.00M$262.60M
Revenue growth (YoY)+47.5%-0.9%-4.3%-0.3%
Gross margin83.3% (computed)74.5% (computed)n/an/a
Operating margin9.9%16.3%-156.3%-45.1%
Net margin-2.3%13.6%-142.9%-30.8%
Net income-$5.34M$31.11M-$353.00M-$80.80M
EPS (Diluted)-$0.02$0.61-$3.29-$1.14
Operating cash flow$67.99M$41.80M-$482.00M-$273.80M
Free cash flow$67.70M$41.73M-$484.00M-$275.70M
Cash & equivalents$184.84M$29.64M$222.00M$142.90M
Total assets$376.56M$216.30M$1.14B$717.90M
Total liabilities$343.95M$85.96Mn/a$284.00M
Shareholders' equity$32.61M$130.34M$631.00M$433.90M
Return on year-end equity-16.4%23.9%-55.9%-18.6%
Shares outstanding265.42M50.41M125.30M63.50M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAkebia Therapeutics, Inc.Puma Biotechnology, Inc.Arcus Biosciences, Inc.Arvinas, Inc.
Latest$236.20M
Ended 2025-12-31		$228.37M
Ended 2025-12-31		$247.00M
Ended 2025-12-31		$262.60M
Ended 2025-12-31
1 year earlier$160.18M
Ended 2024-12-31		$230.47M
Ended 2024-12-31		$258.00M
Ended 2024-12-31		$263.40M
Ended 2024-12-31
2 years earlier$194.62M
Ended 2023-12-31		$235.64M
Ended 2023-12-31		$117.00M
Ended 2023-12-31		$78.50M
Ended 2023-12-31
3 years earlier$292.48M
Ended 2022-12-31		$228.03M
Ended 2022-12-31		$112.00M
Ended 2022-12-31		$131.40M
Ended 2022-12-31
4 years earlier$211.65M
Ended 2021-12-31		$253.16M
Ended 2021-12-31		$383.00M
Ended 2021-12-31		$53.60M
Ended 2021-12-31